DIANORM M 80/500MG TABLET 15'S

DIANORM M 80/500MG TABLET is used to treat type 2 diabetes mellitus, especially when diet and exercise are not enough to control blood sugar levels adequately.

DIANORM M 80/500MG TABLET is a combination of two medicines: Gliclazide and Metformin. Gliclazide belongs to the class of medicines called sulfonylureas and works by increasing the release of insulin from the pancreas. Metformin belongs to the class of medicines called biguanides and works by decreasing the amount of glucose produced by the liver and by increasing the body's sensitivity to insulin.

Common side effects of DIANORM M 80/500MG TABLET include nausea, vomiting, diarrhea, abdominal pain, and loss of appetite.

Yes, DIANORM M 80/500MG TABLET can cause hypoglycemia (low blood sugar), especially if meals are skipped, strenuous exercise is performed, or other antidiabetic medications are being taken.

Store DIANORM M 80/500MG TABLET at room temperature, away from direct sunlight and moisture. Keep it out of reach of children.

DIANORM M 80/500MG TABLET should be used with caution in patients with kidney disease. The dosage may need to be adjusted according to kidney function. It is important to consult a doctor before using it.

DIANORM M 80/500MG TABLET is not recommended for use during pregnancy. Insulin is generally preferred during pregnancy. Consult your doctor if you are pregnant or planning to become pregnant.

DIANORM M 80/500MG TABLET is not recommended for use in breastfeeding women, as it may pass into breast milk and harm the baby.

Drinking alcohol with DIANORM M 80/500MG TABLET is not recommended, as it can increase the risk of hypoglycemia and other side effects.

DIANORM M 80/500MG TABLET can interact with several medications, including other antidiabetic drugs, certain antibiotics, and some heart medications. Inform your doctor if you are taking any other medications.

An overdose of DIANORM M 80/500MG TABLET can cause hypoglycemia. If you or someone else takes an overdose of DIANORM M 80/500MG TABLET, seek immediate medical attention.

DIANORM M 80/500MG TABLET is usually recommended to be taken with or immediately after food to avoid stomach upset and reduce the risk of hypoglycemia.

It may take a few days to a few weeks for DIANORM M 80/500MG TABLET to show its effect. It depends on the individual's condition and response to the medication.

Other medicines containing Gliclazide and Metformin include Glimisave M, Metaglip and Glucovance.

If you forget a dose of DIANORM M 80/500MG TABLET, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose.

Dianorm M is an oral antidiabetic medicine that combines two active ingredients, gliclazide (a sulfonylurea) and metformin (a biguanide). It is used to manage blood glucose levels in adults with type 2 diabetes mellitus when diet, exercise, and treatment with a single oral antidiabetic drug are not sufficient. It helps reduce both fasting and post‑meal blood sugar as part of a comprehensive diabetes management plan.

Dianorm M works through two complementary mechanisms. Gliclazide stimulates the pancreatic beta cells to release more insulin and improves the body’s response to insulin, thereby lowering blood glucose. Metformin reduces glucose production in the liver, decreases absorption of glucose from the intestine, and increases peripheral uptake and utilization of glucose. Together, these actions help improve overall glycemic control in type 2 diabetes.

No, Dianorm M is not indicated for type 1 diabetes mellitus. Type 1 diabetes is characterized by an absolute deficiency of insulin, and insulin injections are required for treatment. Dianorm M relies partly on functioning pancreatic beta cells to stimulate insulin release, which are absent or severely impaired in type 1 diabetes. It should also not be used to treat diabetic ketoacidosis.

Common side effects of Dianorm M include gastrointestinal symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, and loss of appetite, particularly when starting therapy or after dose escalation. Hypoglycemia (low blood sugar) can occur due to the gliclazide component and may present with sweating, tremor, hunger, palpitations, headache, dizziness, or confusion. These effects are usually mild to moderate, but persistent or severe symptoms require medical evaluation.

Signs of hypoglycemia while taking Dianorm M may include sweating, shakiness, intense hunger, palpitations, anxiety, tingling around the lips, headache, dizziness, blurred vision, irritability, difficulty concentrating, or confusion. In severe cases, seizures or loss of consciousness can occur. If mild symptoms appear, the patient should consume fast‑acting carbohydrates such as glucose tablets, sugar, or sweet juice and recheck blood glucose if possible. Severe symptoms require urgent medical attention.

Dianorm M is generally contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe kidney impairment, significant liver disease, acute conditions that may alter kidney function (such as severe dehydration, severe infection, or shock), uncontrolled heart or respiratory failure, and in those with a history of lactic acidosis. It should not be used in individuals with known hypersensitivity to gliclazide, metformin, other sulfonylureas, or any component of the formulation. Suitability must always be assessed by a healthcare professional.

Use of Dianorm M during pregnancy is generally not preferred because tight glycemic control with insulin is usually recommended to minimize risks to the mother and fetus. Data on the safety of the combination of gliclazide and metformin in pregnancy are limited. Women who are pregnant, planning pregnancy, or who become pregnant while taking Dianorm M should consult their doctor promptly. The physician may switch therapy to insulin and adjust the treatment plan according to current clinical guidelines.

Metformin is known to pass into breast milk in small amounts, and available data suggest a low risk to the infant, whereas information on gliclazide excretion into breast milk is limited. Because of the potential for hypoglycemia in the breastfed infant and limited safety data for the combination, the decision to use Dianorm M during breastfeeding must be individualized. The doctor may recommend alternative therapy, such as insulin, or advise discontinuation of breastfeeding depending on the clinical situation.

Alcohol intake should be limited or avoided while taking Dianorm M. Alcohol can increase the risk of hypoglycemia, especially when combined with sulfonylureas like gliclazide, and can also potentiate the risk of lactic acidosis associated with metformin, particularly in patients with impaired liver or kidney function or poor nutritional status. Patients should discuss their alcohol consumption with their healthcare provider and receive individualized advice.

Before major surgery, procedures requiring fasting, or radiological examinations using iodinated contrast agents, the treating physician should be informed that the patient is taking Dianorm M. Metformin may need to be temporarily discontinued before or at the time of the procedure and restarted only after kidney function has been reassessed and found to be stable. The doctor will provide specific instructions on when to stop and restart the medicine and how to manage blood glucose during this period.

Metformin is generally weight‑neutral or may be associated with modest weight reduction, while sulfonylureas such as gliclazide can be associated with weight gain due to increased insulin levels and improved glycemic control. The overall effect of Dianorm M on body weight varies between individuals and depends on diet, physical activity, and baseline metabolic status. Lifestyle measures, including a balanced diet and regular exercise, remain essential to support weight management during treatment.